Please use this identifier to cite or link to this item:
|Title:||DSC and EPR investigations on effects of cholesterol component on molecular interactions between paclitaxel and phospholipid within lipid bilayer membrane||Authors:||Zhao, L.
Differential scanning calorimetry (DSC)
Electron paramagnetic resonance spectroscopy (EPR)
|Issue Date:||29-Jun-2007||Citation:||Zhao, L., Feng, S.-S., Kocherginsky, N., Kostetski, I. (2007-06-29). DSC and EPR investigations on effects of cholesterol component on molecular interactions between paclitaxel and phospholipid within lipid bilayer membrane. International Journal of Pharmaceutics 338 (1-2) : 258-266. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ijpharm.2007.01.045||Abstract:||Differential scanning calorimetry (DSC) and electron paramagnetic resonance spectroscopy (EPR) were applied to investigate effects of cholesterol component on molecular interactions between paclitaxel, which is one of the best antineoplastic agents found from nature, and dipalmitoylphosphatidylcholine (DPPC) within lipid bilayer vesicles (liposomes), which could also be used as a model cell membrane. DSC analysis showed that incorporation of paclitaxel into the DPPC bilayer causes a reduction in the cooperativity of bilayer phase transition, leading to a looser and more flexible bilayer structure. Including cholesterol component in the DPPC/paclitaxel mixed bilayer can facilitate the molecular interaction between paclitaxel and lipid and make the tertiary system more stable. EPR analysis demonstrated that both of paclitaxel and cholesterol have fluidization effect on the DPPC bilayer membranes although cholesterol has more significant effect than paclitaxel does. The reduction kinetics of nitroxides by ascorbic acid showed that paclitaxel can inhibit the reaction by blocking the diffusion of either the ascorbic acid or nitroxide molecules since the reaction is tested to be a first order one. Cholesterol can remarkably increase the reduction reaction speed. This research may provide useful information for optimizing liposomal formulation of the drug as well as for understanding the pharmacology of paclitaxel. © 2007 Elsevier B.V. All rights reserved.||Source Title:||International Journal of Pharmaceutics||URI:||http://scholarbank.nus.edu.sg/handle/10635/63752||ISSN:||03785173||DOI:||10.1016/j.ijpharm.2007.01.045|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.